Dear Doctor - Participate in the Survey on fungal infection "A new survey has found that fungal infections are becoming more common among adults in the United States. The survey, which was conducted by the Centers for Disease Control and Prevention (CDC), found that the number of adults who reported having a fungal infection in the past year had increased from 1.5 percent in 2011 to 2.7 percent in 2016.Fungal infections can cause a variety of symptoms, including itching, redness, and swelling. They can also be difficult to treat, and some types of fungi are resistant to antifungal medications.The CDC recommends that people take steps to prevent fungal infections by keeping their skin clean and dry, avoiding contact with contaminated surfaces, and wearing appropriate footwear when walking in public places. Participate now."
1.
Examines Office-Based Transperineal Prostate Biopsies Methodology.
2.
Patients value communication skills from cancer surgeons across six key areas, according to research
3.
Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients
4.
Underprescribed for Alcohol Use Disorder is pharmacotherapy.
5.
A new mechanism of radioresistance formation demonstrated in lung adenocarcinoma
1.
Transfusing the Future: Exploring the Possibilities of Blood Transfusions
2.
Survivin as a Key Regulator in Gynecological Cancers: Therapeutic and Prognostic Implications
3.
Iron Deficiency Anemia: Challenges in Diagnosis and Treatment
4.
Navigating the Challenges of Vaso-Occlusive Crisis: A Guide for Patients and Caregivers
5.
The Potential of Amifostine in Cancer Treatment: A Revolutionary Breakthrough
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
2.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
3.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
4.
Updates on the First Line Management of ALK+ NSCLC
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation